

Schizophrenia (Central Nervous System) - Drugs in Development, 2021

<https://marketpublishers.com/r/SFA62387E7E3EN.html>

Date: September 2021

Pages: 513

Price: US\$ 2,500.00 (Single User License)

ID: SFA62387E7E3EN

Abstracts

Schizophrenia (Central Nervous System) - Drugs in Development, 2021

SUMMARY

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Schizophrenia - Drugs In Development, 2021, provides an overview of the Schizophrenia (Central Nervous System) pipeline landscape. Schizophrenia is a chronic, severe, and disabling brain disorder that generally appears in late adolescence or early adulthood. Symptoms include delusions, hallucinations, disorganized speech and disorganized behavior. Risk factors include family history, age, drugs (psychoactive) and weakened immune system. Treatment includes antipsychotic medications.

REPORT HIGHLIGHTS

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Schizophrenia - Drugs In Development, 2021, provides comprehensive information on the therapeutics under development for Schizophrenia (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. The Schizophrenia (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Schizophrenia and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages

are 6, 2, 12, 18, 26, 5, 65, 17 and 1 respectively. Similarly, the Universities portfolio in Phase II, Phase I, Preclinical and Discovery stages comprises 2, 1, 5 and 1 molecules, respectively.

Schizophrenia (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

SCOPE

The pipeline guide provides a snapshot of the global therapeutic landscape of Schizophrenia (Central Nervous System).

The pipeline guide reviews pipeline therapeutics for Schizophrenia (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources.

The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

The pipeline guide reviews key companies involved in Schizophrenia (Central Nervous System) therapeutics and enlists all their major and minor projects.

The pipeline guide evaluates Schizophrenia (Central Nervous System) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

The pipeline guide reviews latest news related to pipeline therapeutics for Schizophrenia (Central Nervous System)

REASONS TO BUY

Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

Find and recognize significant and varied types of therapeutics under development for Schizophrenia (Central Nervous System).

Classify potential new clients or partners in the target demographic.

Develop tactical initiatives by understanding the focus areas of leading companies.

Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.

Formulate corrective measures for pipeline projects by understanding Schizophrenia (Central Nervous System) pipeline depth and focus of Indication therapeutics.

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Contents

Introduction

Schizophrenia - Overview

Schizophrenia - Therapeutics Development

Schizophrenia - Therapeutics Assessment

Schizophrenia - Companies Involved in Therapeutics Development

Schizophrenia - Drug Profiles

Schizophrenia - Dormant Projects

Schizophrenia - Discontinued Products

Schizophrenia - Product Development Milestones

Appendix

List Of Tables

LIST OF TABLES

Number of Products under Development for Schizophrenia, 2021
Number of Products under Development by Companies, 2021
Number of Products under Development by Companies, 2021 (Contd..1)
Number of Products under Development by Companies, 2021 (Contd..2)
Number of Products under Development by Companies, 2021 (Contd..3)
Number of Products under Development by Companies, 2021 (Contd..4)
Number of Products under Development by Companies, 2021 (Contd..5)
Number of Products under Development by Universities/Institutes, 2021
Products under Development by Companies, 2021
Products under Development by Companies, 2021 (Contd..1)
Products under Development by Companies, 2021 (Contd..2)
Products under Development by Companies, 2021 (Contd..3)
Products under Development by Companies, 2021 (Contd..4)
Products under Development by Companies, 2021 (Contd..5)
Products under Development by Companies, 2021 (Contd..6)
Products under Development by Companies, 2021 (Contd..7)
Products under Development by Companies, 2021 (Contd..8)
Products under Development by Universities/Institutes, 2021
Number of Products by Stage and Target, 2021
Number of Products by Stage and Target, 2021 (Contd..1)
Number of Products by Stage and Target, 2021 (Contd..2)
Number of Products by Stage and Target, 2021 (Contd..3)
Number of Products by Stage and Mechanism of Action, 2021
Number of Products by Stage and Mechanism of Action, 2021 (Contd..1)
Number of Products by Stage and Mechanism of Action, 2021 (Contd..2)
Number of Products by Stage and Mechanism of Action, 2021 (Contd..3)
Number of Products by Stage and Route of Administration, 2021
Number of Products by Stage and Molecule Type, 2021
Schizophrenia - Pipeline by 3Z ehf, 2021
Schizophrenia - Pipeline by AbbVie Inc, 2021
Schizophrenia - Pipeline by Acadia Pharmaceuticals Inc, 2021
Schizophrenia - Pipeline by Adamed Sp zoo, 2021
Schizophrenia - Pipeline by Adare Pharma Solutions, 2021
Schizophrenia - Pipeline by Adeptio Pharmaceuticals Ltd, 2021
Schizophrenia - Pipeline by AgeneBio Inc, 2021

Schizophrenia - Pipeline by AgoneX Biopharmaceuticals Inc, 2021
Schizophrenia - Pipeline by Alexza Pharmaceuticals Inc, 2021
Schizophrenia - Pipeline by Athersys Inc, 2021
Schizophrenia - Pipeline by Autifony Therapeutics Ltd, 2021
Schizophrenia - Pipeline by Avanir Pharmaceuticals Inc, 2021
Schizophrenia - Pipeline by Avicanna Inc, 2021
Schizophrenia - Pipeline by Avineuro Pharmaceuticals Inc, 2021
Schizophrenia - Pipeline by BCWorld Pharm Co Ltd, 2021
Schizophrenia - Pipeline by Beloteca Inc, 2021
Schizophrenia - Pipeline by Benuvia Therapeutics Inc, 2021
Schizophrenia - Pipeline by Biogen Inc, 2021
Schizophrenia - Pipeline by BioXcel Therapeutics Inc, 2021
Schizophrenia - Pipeline by Boehringer Ingelheim International GmbH, 2021
Schizophrenia - Pipeline by Bristol-Myers Squibb Co, 2021
Schizophrenia - Pipeline by Celon Pharma SA, 2021
Schizophrenia - Pipeline by Cerevance Inc, 2021
Schizophrenia - Pipeline by Cerevel Therapeutics Holdings Inc, 2021
Schizophrenia - Pipeline by Curemark LLC, 2021
Schizophrenia - Pipeline by CuroNZ Ltd, 2021
Schizophrenia - Pipeline by Cycleron Therapeutics Inc, 2021
Schizophrenia - Pipeline by Daewoong Pharmaceutical Co Ltd, 2021
Schizophrenia - Pipeline by Daya Drug Discoveries Inc, 2021
Schizophrenia - Pipeline by Delpor Inc, 2021
Schizophrenia - Pipeline by Denovo Biopharma LLC, 2021
Schizophrenia - Pipeline by Echo Pharmaceuticals BV, 2021
Schizophrenia - Pipeline by F. Hoffmann-La Roche Ltd, 2021
Schizophrenia - Pipeline by Fabre-Kramer Pharmaceuticals Inc, 2021
Schizophrenia - Pipeline by Gabather AB, 2021
Schizophrenia - Pipeline by Genentech USA Inc, 2021
Schizophrenia - Pipeline by Genochem SAS, 2021
Schizophrenia - Pipeline by GP Pharm SA, 2021
Schizophrenia - Pipeline by H. Lundbeck AS, 2021
Schizophrenia - Pipeline by IntelGenx Corp, 2021
Schizophrenia - Pipeline by Intra-Cellular Therapies Inc, 2021
Schizophrenia - Pipeline by INVENT Pharmaceuticals Inc, 2021
Schizophrenia - Pipeline by Io Therapeutics Inc, 2021
Schizophrenia - Pipeline by Jaguar Health Inc, 2021
Schizophrenia - Pipeline by Jazz Pharmaceuticals Plc, 2021
Schizophrenia - Pipeline by Jiangsu Enhua Pharmaceutical Group Co Ltd, 2021

Schizophrenia - Pipeline by Jiangsu Nhwa Pharmaceutical Co Ltd, 2021
Schizophrenia - Pipeline by Johnson & Johnson, 2021
Schizophrenia - Pipeline by Karuna Therapeutics Inc, 2021
Schizophrenia - Pipeline by Laboratorios Farmaceuticos Rovi SA, 2021
Schizophrenia - Pipeline by LB Pharmaceuticals Inc, 2021
Schizophrenia - Pipeline by Lead Discovery Center GmbH, 2021
Schizophrenia - Pipeline by Livzon Pharmaceutical Group Co Ltd, 2021
Schizophrenia - Pipeline by Lohocla Research Corp, 2021
Schizophrenia - Pipeline by Luye Pharma Group Ltd, 2021
Schizophrenia - Pipeline by Lyndra Therapeutics Inc., 2021
Schizophrenia - Pipeline by MapLight therapeutics Inc, 2021
Schizophrenia - Pipeline by MedinCell SA, 2021
Schizophrenia - Pipeline by Mental-Heal Ltd, 2021
Schizophrenia - Pipeline by Merck & Co Inc, 2021
Schizophrenia - Pipeline by Midatech Pharma Plc, 2021
Schizophrenia - Pipeline by Mitsubishi Tanabe Pharma Corp, 2021
Schizophrenia - Pipeline by Nanomi BV, 2021
Schizophrenia - Pipeline by Neonc Technologies Inc, 2021
Schizophrenia - Pipeline by Neurocea Pharmaceuticals, 2021
Schizophrenia - Pipeline by Neurocrine Biosciences Inc, 2021
Schizophrenia - Pipeline by NeurOp Inc, 2021
Schizophrenia - Pipeline by NeuroSolis Inc, 2021
Schizophrenia - Pipeline by Newron Pharmaceuticals SpA, 2021
Schizophrenia - Pipeline by Novartis AG, 2021
Schizophrenia - Pipeline by Omeros Corp, 2021
Schizophrenia - Pipeline by Oryzon Genomics SA, 2021
Schizophrenia - Pipeline by Otsuka Holdings Co Ltd, 2021
Schizophrenia - Pipeline by Otsuka Pharmaceutical Co Ltd, 2021
Schizophrenia - Pipeline by OWP Pharmaceuticals Inc, 2021
Schizophrenia - Pipeline by Ra Pharmaceuticals Inc, 2021
Schizophrenia - Pipeline by Reviva Pharmaceuticals Inc, 2021
Schizophrenia - Pipeline by Richter Gedeon Nyrt, 2021
Schizophrenia - Pipeline by Saniona AB, 2021
Schizophrenia - Pipeline by Schrodinger Inc, 2021
Schizophrenia - Pipeline by Shanghai Zhongze Medicine Tech Co Ltd, 2021
Schizophrenia - Pipeline by Sichuan Kelun Pharmaceutical Co Ltd, 2021
Schizophrenia - Pipeline by Siragen Pharmaceuticals Inc, 2021
Schizophrenia - Pipeline by Sirtsei Pharmaceuticals Inc, 2021
Schizophrenia - Pipeline by SkySea Pharmaceutical Inc, 2021

Schizophrenia - Pipeline by Sosei Group Corp, 2021
Schizophrenia - Pipeline by Sumitomo Dainippon Pharma Co Ltd, 2021
Schizophrenia - Pipeline by Sunovion Pharmaceuticals Inc, 2021
Schizophrenia - Pipeline by Suven Life Sciences Ltd, 2021
Schizophrenia - Pipeline by SyneuRx International Corp, 2021
Schizophrenia - Pipeline by Tahoe Pharmaceuticals Ltd, 2021
Schizophrenia - Pipeline by Taisho Pharmaceutical Holdings Co Ltd, 2021
Schizophrenia - Pipeline by Takeda Pharmaceutical Co Ltd, 2021
Schizophrenia - Pipeline by Terran Biosciences Inc, 2021
Schizophrenia - Pipeline by Teva Pharmaceutical Industries Ltd, 2021
Schizophrenia - Pipeline by The Greater Cannabis Company Inc, 2021
Schizophrenia - Pipeline by Therapeutic Solutions International Inc, 2021
Schizophrenia - Pipeline by Valentec, 2021
Schizophrenia - Pipeline by Vanda Pharmaceuticals Inc, 2021
Schizophrenia - Pipeline by Verge Genomics Inc, 2021
Schizophrenia - Pipeline by Viatrix Inc, 2021
Schizophrenia - Pipeline by Vitality Biopharma Inc, 2021
Schizophrenia - Pipeline by Whan In Pharm Co Ltd, 2021
Schizophrenia - Pipeline by Zhejiang Jingxin Pharmaceutical Co Ltd, 2021
Schizophrenia - Pipeline by Zysis Ltd, 2021
Schizophrenia - Dormant Projects, 2021
Schizophrenia - Dormant Projects, 2021 (Contd..1)
Schizophrenia - Dormant Projects, 2021 (Contd..2)
Schizophrenia - Dormant Projects, 2021 (Contd..3)
Schizophrenia - Dormant Projects, 2021 (Contd..4)
Schizophrenia - Dormant Projects, 2021 (Contd..5)
Schizophrenia - Dormant Projects, 2021 (Contd..6)
Schizophrenia - Dormant Projects, 2021 (Contd..7)
Schizophrenia - Dormant Projects, 2021 (Contd..8)
Schizophrenia - Dormant Projects, 2021 (Contd..9)
Schizophrenia - Dormant Projects, 2021 (Contd..10)
Schizophrenia - Discontinued Products, 2021
Schizophrenia - Discontinued Products, 2021 (Contd..1)
Schizophrenia - Discontinued Products, 2021 (Contd..2)

List Of Figures

LIST OF FIGURES

- Number of Products under Development for Schizophrenia, 2021
- Number of Products under Development by Companies, 2021
- Number of Products under Development by Universities/Institutes, 2021
- Number of Products by Top 10 Targets, 2021
- Number of Products by Stage and Top 10 Targets, 2021
- Number of Products by Top 10 Mechanism of Actions, 2021
- Number of Products by Stage and Top 10 Mechanism of Actions, 2021
- Number of Products by Top 10 Routes of Administration, 2021
- Number of Products by Stage and Top 10 Routes of Administration, 2021
- Number of Products by Molecule Types, 2021
- Number of Products by Stage and Molecule Types, 2021

I would like to order

Product name: Schizophrenia (Central Nervous System) - Drugs in Development, 2021

Product link: <https://marketpublishers.com/r/SFA62387E7E3EN.html>

Price: US\$ 2,500.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/SFA62387E7E3EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970